US FDA News: Statement on the FDA’s benefit-risk framework for evaluating opioid analgesics

FDA issues a new draft guidance on the application of the benefit-risk assessment framework for evaluating applications for opioids.
Read more: Statement on the FDA’s benefit-risk framework for evaluating opioid analgesics